Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27262151 | 1.00 | PRMT1 (0.68) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL2807061 | 0.95 | PRMT1 (0.60) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL8766161 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL8766995 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL31317597 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL24483715 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL8507619 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL17767810 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL22506195 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA | |
| SCHEMBL11468363 | 0.93 | PRMT1 (0.71) | PRMT1ADRA1AEPHX2MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| CN-102405039-A | Cosmetic or dermatological composition comprising a polymer containing linking groups, and cosmetic treatment method | OREAL | 2012-04-04 | — | — | CN | claimed |
| CN-102325518-A | Cosmetic or pharmaceutical composition comprising a polycondensate, polycondensate and method of cosmetic treatment | OREAL | 2012-01-18 | — | — | CN | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| EP-4204100-A1 | HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE | L'OREAL (FR) | 2023-07-05 | — | — | EP | disclosed |
| US-11559474-B2 | Hair lightening compositions and methods of use | L'OREAL (FR) | 2023-01-24 | — | — | US | disclosed |
| WO-2022047081-A1 | HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE | HENRY DEREK (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2018119500-A1 | VISCOELASTIC COSMETIC COMPOSITIONS | L'OREAL (FR) | 2018-07-05 | — | — | WO | disclosed |
| CN-102405039-B | Comprise cosmetics or skin composition and cosmetic treatment method containing the polymer of connecting group | 莱雅公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | disclosed |
| CN-102405039-A | Cosmetic or dermatological composition comprising a polymer containing linking groups, and cosmetic treatment method | OREAL | 2012-04-04 | — | — | CN | disclosed |
| CN-102325518-A | Cosmetic or pharmaceutical composition comprising a polycondensate, polycondensate and method of cosmetic treatment | OREAL | 2012-01-18 | — | — | CN | disclosed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | disclosed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | L'OREAL (FR) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | PRMT1 4663/4885ADRA1A 4844/4885EPHX2 301/4885 |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | CUTA, SYMPK, TPRKB | PRMT1 2654/4885ADRA1A 4879/4885EPHX2 3893/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | PRMT1 2072/4885ADRA1A 4380/4885EPHX2 771/4885 |
| US-11559474-B2 | Hair lightening compositions and methods of use | TYR, ALAD, CYBA | PRMT1 1066/4885ADRA1A 4779/4885EPHX2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.